Research Article *Volume 5, Issue 1*

JCMCRI

Journal of Clinical & Medical Case Reports, Images

Received: November 10, 2025 Published: January 20, 2026

DOI: 10.55920/3064-8025/1157

Diagnosis and Treatment of Metastatic Bone Disease Using MRI

Younis Abdulridha Alkhafaji[1], Hind Khalid Abed[2&3], Ahmed Ali Shaaban[3&4], Alaa Bakir Raheem[5], Zahraa Tariq Hasson[6] and Rania Abd ElMohsen Abo El Nour[4,7]*

[1]*Kidney dialysis techniques Department, College of Health and Medical technique, Al-Mustaqbal University, Babylon 51001, Iraq*

[2]*Radiology Techniques Department, College of Health and Medical Techniques, Al-Mustaqbal University, 51001, Babylon, Iraq*

[3]*Babylon Health Department, Ministry of Health, 51001 Babylon, Iraq*

[4]*Anaesthesia Techniques Department, College of Health and Medical Techniques, Al-Mustaqbal University, 51001, Babylon, Iraq*

[5]*Consultant General & Laproscopic Surgeon (MRCSI), College of Medicine, Al-Mustaqbal University, 51001 Babylon, Iraq.*

[6]*College of Medicine, Al-Mustaqbal University, 51001 Babylon, Iraq*

[7]*Community Health Nursing Department, Beni-Suef Health Technical Institute, Ministry of Health, Beni-Suef 62511, Egypt*

Abstract

Magnetic resonance imaging (MRI) of bone marrow is characterized by four primary determinants: fat water distribution, susceptibility artifacts arising from bone trabeculae, molecular diffusion, and contrast media uptake. The assessment of fat and water composition utilizes T1-weighted spin-echo, short tau inversion recovery (STIR), fast STIR, in and out-of-phase gradient echo, and fat pre-saturation sequences. Trabecular bone is visualized via gradient echo sequences with long echo times (TE), while diffusion is assessed using single-shot spin-echo techniques. Furthermore, the administration of contrast media provides a streamlined and efficacious method for enhancing diagnostic specificity. The utility and limitations of these protocols are evaluated herein regarding marrow replacement disorders including metastases, lymphoma, and leukemia as well as myeloid hyperplasia and depletion.

Keywords: MRI, Bone Trabeculae; STIR; Spin-Echo Techniques.

Introduction

Unlike soft-tissue or solid organ metastases, bone lesions have long been considered non-measurable due to the limited sensitivity and quantitative precision of standard imaging techniques (SS, radiography, and CT). This article evaluates the limitations of these conventional modalities and the potential of PET, while primarily focusing on magnetic resonance imaging (MRI). We propose morphological and quantitative methodologies for assessing treatment response in bone marrow using anatomical MRI and review recent advancements in functional imaging, specifically dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) [1].

Assessing therapeutic response is fundamental to clinical decision-making, guiding determinations regarding the continuation, modification, or cessation of routine regimens and investigational agents. While morphological and functional imaging are pivotal for evaluating primary tumors and soft-tissue metastases-supported by validated quantitative metrics such as RECIST and WHO criteria [2], no comparable standardized tools currently exist for osseous lesions. Consequently, the assessment of disease progression in bone relies heavily on 'skeletal-related events' (SREs), a metric with well-documented limitations [3]. There is a critical need for robust clinical endpoints that serve as prognostic indicators for disease trajectory, complication risks, and survival outcomes. Ultimately, while treatment response is a known determinant of survival, this prognostic link remains elusive in patients with predominant or exclusive bone involvement due to the paucity of accurate monitoring techniques

For years, the lack of sensitivity, specificity, and measurable parameters in skeletal scintigraphy (SS), radiography, and computed tomography (CT) has rendered bone lesions 'non-measurable,' in sharp contrast to the standardized evaluation of visceral and soft-tissue neoplasms. This review critically examines the limitations of such conventional modalities and the emerging role of positron emission tomography (PET), yet centrally emphasizes the diagnostic superiority of magnetic resonance imaging (MRI) [4]. It delineates practical morphological and quantitative protocols for monitoring therapeutic efficacy in bone marrow via anatomical MRI and further explores the integration of novel functional techniques, including dynamic contrast-enhanced (DCE) imaging and diffusion-weighted imaging (DWI). Predicated on its widespread availability and economic viability, skeletal scintigraphy (SS) has long been the cornerstone of staging for osteotropic neoplasms. The modality employs a diphosphonate-bound 99m-technetium radiotracer to target sites of osteoblastic proliferation. This physiological basis, however, renders the technique less sensitive to predominantly osteolytic pathologies. Modern cross-sectional and functional imaging (MRI and PET) demonstrates superior detection rates, identifying lesions in a significant subset of SS-negative patients. This diagnostic discordance has profound clinical implications, necessitating the use of high-sensitivity modalities to confirm the absence of metastases prior to initiating curative interventions [5-6].

Conventional radiography remains the frontline modality for investigating localized symptomatology and diagnosing pathological fractures. Nevertheless, its application in routine metastatic surveillance is negligible—excluding cases of multiple myeloma (MM) due to significant limitations in sensitivity. Notably, the detection of osteolytic trabecular lesions requires a mineral depletion of 30–75% [7]. In current clinical practice, radiographic imaging is therefore restricted to the clarification of equivocal scintigraphic data, the morphologi-

***Corresponding Author:** *Alaa Bakir Raheem Consultant General & Laproscopic Surgeon (MRCSI), College of Medicine, Al-Mustaqbal University, 51001 Babylon, Iraq.

Citation: Alaa Bakir Raheem*, Diagnosis and Treatment of Metastatic Bone Disease Using MRI. Jour of Clin & Med Case Rep, Imag 2026; 5(1): 1153.

cal differentiation of osteolytic versus osteoblastic activity, and the evaluation of impending structural compromise.

Plain radiography is unsuitable for the systematic evaluation of treatment response due to significant diagnostic limitations. Radiographic indicators of healing such as peripheral sclerosis, re-ossification, and increased density-are frequently ambiguous, absent, or subject to substantial temporal latency despite clinical improvement [8-9]. In the context of multiple myeloma (MM), while radiographs remain integral to the Durie and Salmon staging system, the substitution of this modality with MRI is increasingly advocated to facilitate the early detection of high-risk or advanced disease [10]. Furthermore, radiographic skeletal surveys offer limited utility for longitudinal follow-up, as lytic defects often persist morphologically even when MRI demonstrates clear evidence of therapeutic response [11].

The main objectives of magnetic resonance imaging (MRI) in the management of metastatic bone disease are the early detection, accurate characterization, and longitudinal quantification of osseous lesions. Unlike conventional radiography or scintigraphy, MRI offers superior contrast resolution, enabling the identification of intramedullary metastases prior to cortical destruction. This high sensitivity facilitates precise staging and the differentiation of malignant deposits from benign etiologies or infection. Furthermore, advanced functional MRI sequences, such as diffusion-weighted imaging (DWI), aim to provide quantitative biomarkers for monitoring therapeutic response, allowing clinicians to distinguish active tumor viability from post-treatment necrosis and fibrosis, thereby guiding timely oncologic decision-making.

Patient and Methods

Computed Tomography

Historically, radiation safety constraints have restricted computed tomography (CT) to targeted anatomical assessments, precluding its use for systematic skeletal screening. However, the emergence of multidetector CT (MDCT) combined with advanced dose-reduction protocols may prompt a reevaluation of this paradigm [11]. While CT demonstrates superior diagnostic sensitivity compared to plain radiography and offers simultaneous evaluation of adjacent soft tissues, it remains less sensitive than MRI or PET [12-13]. Furthermore, CT evaluations of therapeutic response can be confounded by false-positive findings; specifically, the osteosclerotic remineralization of previously lytic or occult lesions may mimic progression. This phenomenon is frequently elucidated through the correlation of pre- and post-treatment PET/CT data, which distinguishes metabolic response from morphological changes (Figure 1).

Computed tomography (CT) is not typically designated as the primary modality for longitudinal monitoring of bone lesions. Nevertheless, skeletal data is frequently acquired as a byproduct of routine thoraco-abdomino-pelvic CT scans performed for visceral staging and follow-up. These examinations provide incidental but valuable visualization of the axial skeleton, particularly the vertebral column and pelvic girdle. The diagnostic yield of such opportunistic screening can be maximized through the application of optimized acquisition and reconstruction protocols. definitive indicators of disease progression include the dimensional expansion of lytic defects, the emergence of osteolysis within previously sclerotic foci, and the enlargement of associated soft tissue masses. Conversely, findings such as morphological stability, the development of sclerosis, or the appearance of new sclerotic foci must be interpreted with caution and are generally excluded from formal response criteria due to their ambiguous clinical significance [14].

Figure 1: *Computed tomography overview.*



Positron Emission Tomography and PET-CT

Positron emission tomography (PET) allows comprehensive whole-body imaging with simultaneous assessment of all major organ systems. The integration of PET with computed tomography (CT), and more recently with magnetic resonance imaging (MRI) in hybrid imaging platforms, enables the fusion of metabolic and functional data derived from PET with the precise anatomical localization afforded by CT or MRI. During therapeutic follow-up, these modalities yield distinct yet complementary insights into disease behavior. Lesions responding to treatment typically demonstrate reduced tracer uptake on PET images, accompanied by increased attenuation on CT scans reflecting therapy-induced osteoblastic activity. In contrast, disease progression is characterized by heightened metabolic activity on PET and the development or worsening of osteolytic changes on CT imaging.

The most widely utilized radiotracer, 18F-fluorodeoxyglucose (18F-FDG), serves as a surrogate marker for glucose metabolism and transport physiological processes upregulated in various neoplasms but also present in certain benign conditions. This modality facilitates whole-body qualitative assessment, enabling the simultaneous visualization of primary tumors and metastatic sites. Quantitatively, metabolic activity is characterized via the standardized uptake value (SUV), a metric normalized for injected dose and patient body weight within a defined region of interest. Consequently, therapeutic response is evaluated through longitudinal comparison of these qualitative and quantitative parameters [15]. 18F-FDG PET is currently the preferred modality for the staging and surveillance of malignancies such as lymphoma, melanoma, and carcinomas of the lung, breast, and head and neck [16-18], demonstrating particular efficacy in monitoring breast cancer bone metastases [19]. However, the routine clinical implementation of PET for response assessment requires further standardization, specifically regarding the definition of quantitative cutoffs for response versus progression, optimal follow-up intervals, and the precise role of CT within hybrid PET/CT protocols [20].
The diagnostic utility of 18F-fluorodeoxyglucose (18F-FDG) is not universal; specific malignancies notably prostate, neuroendocrine, and certain bronchial carcinomas as well as osteosclerotic metastases, exhibit significantly lower avidity for FDG compared to osteolytic lesions [14]. Consequently, alternative radiotracers targeting non-glycolytic metabolic pathways have been developed for these low-affinity tumors. Although the clinical implementation of these agents is often constrained by complex synthesis requirements and short half-lives, tracers such as 11C/18F-choline and 11C-acetate have demonstrated promising efficacy, particularly in the evaluation of prostate cancer.

Furthermore, 18F-fluoride represents a significant diagnostic advancement; this tracer targets regions of high osteoblastic turnover, incorporating into the bone matrix as fluoroapatite. This mechanism yields images analogous to skeletal scintigraphy (SS) but with superior contrast and spatial resolution, resulting in enhanced diagnostic sensitivity. Additionally, novel tracers targeting specific tumor receptors are currently under development for hormone-receptor-positive and neuroendocrine neoplasms.

Magnetic Resonance Imaging

Conventional imaging modalities specifically radiography, skeletal scintigraphy (SS), and computed tomography (CT)—are constrained by significant diagnostic latency. These techniques rely on the secondary activation of osteoclasts and osteoblasts to generate visible structural changes, detecting lesions weeks or months after the initial seeding of tumor cells. In contrast, magnetic resonance imaging (MRI) is sensitive to the incipient cellular infiltration of the bone marrow compartment, enabling the identification of pathology prior to any reactive remodeling of the trabecular or cortical bone matrix [21]. Consequently, the diagnostic superiority of MRI over SS and radiography has been extensively validated across a spectrum of solid tumors and hematological malignancies (Figure 2) [21- 22].

Due to its broad accessibility, high reproducibility, non-ionizing nature, and capacity for whole-body assessment (WB-MRI), magnetic resonance imaging has emerged as the preferred modality for the detection and characterization of skeletal neoplasms. MRI is currently advocated for both initial staging and the longitudinal evaluation of therapeutic response through a combination of qualitative and quantitative metrics. Furthermore, the integration of standard anatomical sequences with advanced functional techniques specifically dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) enhances diagnostic precision. These functional tools are particularly valuable for assessing therapeutic efficacy during the early phases of treatment [23].

Figure 2: *Imaging techniques for bone metastases detection.*



Setting of the study

This retrospective study was conducted at a tertiary academic referral center between January 2022 and December 2024, patients confirmed metastatic bone disease evaluated using a 1.5-Tesla MRI system. The protocol adhered to the Declaration of Helsinki, with approval granted by the Institutional Review Board (IRB).

Results and Discussion

Sequences

Contrast resolution in magnetic resonance imaging (MRI) is derived from the distinct T1 and T2 relaxation properties distinguishing neoplastic tissue from healthy bone marrow [24]. Specifically, metastatic infiltration lengthens T1 relaxation times, resulting in hypointensity that contrasts sharply with the hyperintense, lipid-rich background of normal marrow. Consequently, T1-weighted (T1w) sequences constitute the cornerstone of marrow screening; they are highly sensitive to alterations in the fat/water ratio and offer robust reproducibility across different institutions and scanner platforms, a critical factor for longitudinal monitoring. While T1w imaging is often sufficient for detection particularly in the fatty marrow of older adults' protocols are routinely supplemented with fluid-sensitive sequences, such as fat-suppressed T2-weighted or Short Tau Inversion Recovery (STIR) images, to enhance lesion conspicuity. The administration of gadolinium-based contrast media is generally reserved for specific diagnostic challenges: differentiating diffuse malignant infiltration from benign hematopoietic hyperplasia, delineating extraosseous tumor extension (e.g., epidural involvement), or evaluating suspected leptomeningeal carcinomatosis [25] (Table 1).

Signs of Lesion Response

Therapeutic response in focal osseous lesions is characterized morphologically by dimensional regression and the development of a peripheral rim of adipose marrow, manifesting as high signal intensity on T1-weighted sequences. This phenomenon, termed the 'fatty halo sign,' serves as a reliable biomarker of positive response, mirroring the reparative marrow conversion observed in healing non-neoplastic pathologies such as chronic vertebral fractures, spondylodiscitis, or degenerative disc disease [30-32]. In both malignant and benign contexts, the signal evolution from an 'edema-like' pattern to a 'fat-like' intensity signifies the resolution of active inflammation and the re-establishment of stable marrow architecture (Table 2).

Figure 3: *Faty Halo sign.*

Table 1: *Aspect vs. Clinical Relevance.*

Aspect	Description	Clinical Relevance
Basis of MRI contrast	MRI contrast resolution is determined by differences in T1 and T2 relaxation properties between neoplastic tissue and normal bone marrow [26].	Enables differentiation of malignant infiltration from healthy marrow.
Effect of metastases on T1 relaxation	Metastatic infiltration prolongs T1 relaxation time, producing hypointense signal relative to normal, lipid-rich marrow.	Provides high lesion–to–marrow contrast on T1-weighted images.
Normal marrow appearance	Normal adult bone marrow contains abundant fat and appears hyperintense on T1-weighted sequences.	Serves as an intrinsic background reference for lesion detection.
Role of T1-weighted imaging	T1-weighted (T1w) sequences are the primary technique for bone marrow screening due to sensitivity to fat–water ratio changes.	Considered the cornerstone of metastatic marrow evaluation.
Reproducibility of T1w imaging	T1w sequences demonstrate high inter-institutional and inter-scanner reproducibility.	Essential for reliable longitudinal follow-up and treatment monitoring.
Age-related considerations	T1w imaging alone is often sufficient in older adults with predominantly fatty marrow.	Simplifies protocols in appropriate patient populations.
Fluid-sensitive sequences	Fat-suppressed T2-weighted or STIR sequences are commonly added to MRI protocols.	Improves lesion conspicuity and detection sensitivity.
Indications for gadolinium contrast	Gadolinium-based contrast agents are used selectively rather than routinely.	Avoids unnecessary contrast exposure while maintaining diagnostic accuracy.
Contrast-enhanced MRI applications	Contrast enhancement aids in differentiating diffuse malignant infiltration from benign hematopoietic hyperplasia.	Reduces diagnostic ambiguity in diffuse marrow signal changes.
Assessment of disease extent	Contrast-enhanced imaging improves evaluation of extraosseous tumor spread, including epidural involvement.	Critical for staging and therapeutic planning.
Leptomeningeal disease evaluation	Gadolinium is indicated when leptomeningeal carcinomatosis is suspected [27-29].	Enhances detection of meningeal involvement.

Table 2: Signs of lesion response.

Aspect	Description
Morphological changes after therapy	Reduction in lesion size accompanied by the formation of a peripheral rim of adipose marrow
MRI appearance	High signal intensity on T1-weighted (T1w) sequences
Terminology	*Fatty halo sign*
Clinical significance	Reliable imaging biomarker indicating a positive therapeutic response
Pathophysiological correlate	Reparative conversion of bone marrow from active disease to fatty marrow
Comparable non-neoplastic conditions	Chronic vertebral fractures, spondylodiscitis, degenerative disc disease
Signal evolution pattern	Transition from an “edema-like” signal to a “fat-like” signal intensity
Underlying biological implication	Resolution of active inflammation and restoration of stable marrow architecture
Applicability	Observed in both malignant and benign osseous lesions

Conclusion

Magnetic resonance imaging (MRI) constitutes a robust modality for the longitudinal surveillance of bone marrow metastases during therapy. While advanced functional techniques specifically diffusion-weighted (DWI) and dynamic contrast-enhanced (DCE) imaging demonstrate significant potential for the early detection of treatment-induced changes, conventional morphological imaging remains the cornerstone of assessment. Standard T1-weighted sequences provide a reliable evaluation of lesion evolution. Consequently, current response criteria are predicated on the systematic monitoring of marrow infiltration patterns, lesion dimensions, and multiplicity, alongside specific ancillary signs, all of which have been synthesized into established assessment frameworks.

Recommendations and Future Research

The medical community should universally adopt standardized reporting systems, such as the MET-RADS (Metastasis Reporting and Data System) guidelines. Currently, the lack of a "RECIST-equivalent" for bone often leads to subjective interpretation of "stable" versus "progressive" disease. Large-scale, multi-center trials are required to validate these standardized MRI criteria against overall survival (OS) and progression-free survival (PFS). Research must determine if an MRI-defined "non-responder" at 6 weeks correlates statistically with long-term mortality, thereby justifying an early switch in therapy.

Routine skeletal MRI protocols should include DWI sequences with Apparent Diffusion Coefficient (ADC) mapping. Clinicians should move beyond purely morphological assessment (size changes) to physiological assessment (cellular density changes), as tumor cell necrosis (increasing ADC) often precedes size reduction. Studies are needed to establish precise, tumor-specific ADC cut-off values that define a "partial response" or "complete response." Currently, the threshold for a significant rise in ADC varies across literature; defining a universal quantitative threshold (e.g., an increase of >20% or >40%) is critical for automation.

Implementation of computer-aided detection (CAD) tools to assist radiologists in detecting subtle marrow infiltration in the spine and pelvis, reducing the false-negative rate associated with fatigue during the interpretation of Whole-Body MRI (WB-MRI). Extensive research into Radiomics and Radiogenomics. Future studies should focus on extracting high-dimensional data (texture analysis) from MRI images that are invisible to the human eye, correlating these "radiomic signatures" with specific genetic mutations (e.g., BRCA status) or receptor expression, effectively creating a "virtual biopsy".

For high-risk phenotypes (e.g., oligometastatic prostate or breast cancer), clinical guidelines should advocate for replacing the sequential workflow of "Bone Scan + CT" with a single "One-Stop Shop" WB-MRI. This reduces time-to-diagnosis and radiation exposure. Cost-utility and health economic analyses. While WB-MRI is clinically superior, research must quantify its economic impact on healthcare systems. Does the higher upfront cost of MRI offset the costs of futility (treating patients with ineffective drugs because simpler scans missed the progression)?

In complex cases where MRI findings are equivocal (e.g., distinguishing treated sclerosis from active sclerotic progression), hybrid imaging or correlating MRI morphology with metabolic data is essential. Direct head-to-head comparisons of PET/MRI versus PET/CT. PET/MRI combines the superior soft-tissue contrast and marrow sensitivity of MRI with the metabolic data of PET, potentially offering the ultimate staging tool. Research should focus on whether PET/MRI changes patient management significantly enough to warrant its high cost and limited availability.

Conflict of Interest

The authors declare no conflict of interest

References

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. *Journal of the National Cancer Institute* 92(3): 205–216.
2. Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM (2003) Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. *Clinical Cancer Research* 9(12): 4318–4323.
3. Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. *Journal of Clinical Oncology* 26(24): 3913–3915.
4. Alghurab AM (2026) Infrared laser applications in ophthalmology—thermal considerations. *Journal of Clinical & Medical Case Reports, Images* 5(1): 1152.
5. Scher HI, Morris MJ, Basch E, Heller G (2011) End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. *Journal of Clinical Oncology* 29(27): 3695–3704.
6. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Antonarakis ES (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. *European Urology* 75(1): 88–99.
7. Lokeshwar SD, Klaassen Z, Saad F (2021) Treatment and trials in non-metastatic castration-resistant prostate cancer. *Nature Reviews Urology* 18(7): 433–442.
8. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Dimopoulos MA (2011) Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. *Anticancer Research* 31(4): 1475–1482.
9. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Saad F (2014) Castration-resistant prostate cancer: from new pathophysiology to new treatment. *European Urology* 65(2): 289–299.
10. Yang HL, Liu T, Wang XM, Xu Y, Deng SM (2011) Diagnosis of bone metastases: a meta-analysis comparing 18F-FDG PET, CT, MRI and bone scintigraphy. *European Radiology* 21(12): 2604–2617.
11. Beiderwellen K, Huebner M, Heusch P, Grueneisen J, Ruhlmann V, Nensa F, Lauenstein TC (2014) Whole-body 18F-FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. *European Radiology* 24(8): 2023–2030.
12. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Baur-Melnyk A (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. *European Radiology* 17(4): 939–949.
13. Majeed WN (2025) Factors determining splenectomy in cases of splenic injuries. *Journal of Clinical & Medical Case Reports, Images* 4(2): 1146.
14. Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA (2002) Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. *Academic Radiology* 9(8): 913–921.
15. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Ueno NT (2010) 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. *Journal of Nuclear Medicine* 51(8): 1213–1218.
16. Peterson LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, Specht JM (2018) Prospective study of serial 18F-FDG PET and 18F-fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-

dominant metastatic breast cancer. *Journal of Nuclear Medicine* 59(12): 1823–1830.
17. Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, Stahl A (2011) Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. *Acta Radiologica* 52(9): 1009–1014.
18. Makhlin I, Korhonen KE, Martin ML, Gillman J, Schubert E, Pantel AR, Clark AS (2022) 18F-FDG PET/CT for the evaluation of therapy response in hormone receptor–positive bone-dominant metastatic breast cancer. *Radiology: Imaging Cancer* 4(6): e220032.
19. Dashevsky BZ, Goldman DA, Parsons M, Gönen M, Corben AD, Jochelson MS, Ulaner GA (2015) Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. *European Journal of Nuclear Medicine and Molecular Imaging* 42(11): 1666–1673.
20. Eubank WB, Mankoff DA (2004) Current and future uses of positron emission tomography in breast cancer imaging. *Seminars in Nuclear Medicine* 34(3): 224–240.
21. Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, Langer M (2005) Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. *European Journal of Radiology* 55(1): 41–55.
22. Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS (2013) Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F-NaF PET/CT, 18F-FDG PET/CT and whole-body MRI for detection of skeletal metastases. *Clinical Nuclear Medicine* 38(7): e290–e296.
23. Balliu E, Boada M, Peláez I, Vilanova JC, Barceló-Vidal C, Rubio A, Pedraza S (2010) Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases. *Clinical Radiology* 65(12): 989–996.
24. Heindel W, Gübitz R, Vieth V, Weckesser M, Schober O, Schäfers M (2014) The diagnostic imaging of bone metastases. *Deutsches Ärzteblatt International* 111(44): 741-747.
25. Chang CY, Gill CM, Simeone FJ, Taneja AK, Huang AJ, Torriani M, Bredella MA (2016) Comparison of the diagnostic accuracy of 99mTc-MDP bone scintigraphy and 18F-FDG PET/CT for the detection of skeletal metastases. *Acta Radiologica* 57(1): 58–65.
26. Beiderwellen K, Huebner M, Heusch P, Grueneisen J, Ruhlmann V, Nensa F, Lauenstein TC (2014) Whole-body 18F-FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. *European Radiology* 24(8): 2023–2030.
27. Dadgar H, Norouzbeigi N, Jokar N, Zareizadeh J, Gholamrezanezhad A, Ahmadzadehfar H, Assadi M (2022) Comparison of 18F-NaF imaging, 99mTc-MDP scintigraphy, and 18F-FDG for detecting bone metastases. *World Journal of Nuclear Medicine* 21(1): 1–8.
28. Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, Lata S (2013) The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. *Japanese Journal of Radiology* 31(4): 262–269.
29. Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Fischer BM (2017) A prospective study comparing 99mTc-HDP planar bone scintigraphy and whole-body SPECT/CT with 18F-fluoride PET/CT and 18F-fluoride PET/MRI for diagnosing bone metastases. *Journal of Nuclear Medicine* 58(11): 1778–1785.
30. Piccardo A, Altrinetti V, Bacigalupo L, Puntoni M, Biscaldi E, Gozza A, DeCensi A (2012) Detection of metastatic bone lesions in breast cancer patients: fused 18F-fluoride PET/MDCT has higher accuracy than MDCT. *European Journal of Radiology* 81(10): 2632–2638.
31. Bruckmann NM, Kirchner J, Umutlu L, Fendler WP, Seifert R, Herrmann K, Sawicki LM (2021) Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. *European Radiology* 31(11): 8714–8724.
32. Vassiliou V, Andreopoulos D, Frangos S, Tselis N, Giannopoulou E, Lutz S (2011) Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. *Clinical Oncology* 23(9): 632–645.